Brentuximab vedotin complements this by disrupting the microtubule network within CD30-expressing tumor cells leading to apoptosis [7], while also having immunomodulatory activity through induction of immunogenic cell death resulting in activation of innate and adaptive immune cells [44–46]. The gene discussed is TNFRSF8; the disease is neoplasm.